LOG IN
SIGN UP
MARKET
FMTX
FMTX
Forma Therapeutics Holdings, Inc.,
NASDAQ
Real-time Quotes | Nasdaq Last Sale
6.87
-0.37
-5.11%
Opening 15:21 06/24 EDT
OPEN
7.24
PREV CLOSE
7.24
HIGH
7.45
LOW
6.72
VOLUME
385.42K
TURNOVER
1.55M
52 WEEK HIGH
26.90
52 WEEK LOW
4.950
MARKET CAP
328.42M
P/E (TTM)
-1.7980
1D
5D
1M
3M
1Y
5Y
Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 536% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate r...
Zacks · 2d ago
Bears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' Now
Forma Therapeutics Holdings, Inc. (FMTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising ear...
Zacks · 06/15 13:55
Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'
Benzinga · 06/13 18:45
--Cantor Fitzgerald Assumes Forma Therapeutics Holdings at Overweight with $21 Price Target
MT Newswires · 06/13 08:56
Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
WATERTOWN, Mass., June 10, 2022--Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
Business Wire · 06/10 11:22
Forma Therapeutics to Present at the Jefferies Healthcare Conference
WATERTOWN, Mass., June 03, 2022--Forma Therapeutics to Present at the Jefferies Healthcare Conference
Business Wire · 06/03 11:05
SVB Securities Lowers Forma Therapeutics Holdings' Price Target to $23 From $25, Maintains Outperform Rating
MT Newswires · 05/27 10:57
Oppenheimer Adjusts Price Target on Forma Therapeutics Holdings to $46 From $49, Maintains Outperform Rating
MT Newswires · 05/27 09:29
No Data
Learn about the latest financial forecast of FMTX. Analyze the recent business situations of Forma Therapeutics Holdings, Inc., through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 7 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
42.86%Strong Buy
57.14%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FMTX stock price target is 40.29 with a high estimate of 57.00 and a low estimate of 21.00.
Current 7.03
EPS
Actual
Estimate
-0.85-0.64-0.42-0.21
Institutional Holdings
Institutions: 102
Institutional Holdings: 42.81M
% Owned: 89.56%
Shares Outstanding: 47.80M
TypeInstitutionsShares
Increased
36
4.12M
New
16
2.42M
Decreased
27
4.32M
Sold Out
12
1.89M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Frank Lee
Chief Financial Officer/Senior Vice President
Todd Shegog
Chief Human Resource Officer/Senior Vice President
Mary Wadlinger
Senior Vice President/Chief Technology Officer
John Bishop
Senior Vice President/Chief Scientific Officer
David Cook
Senior Vice President/General Counsel/Secretary
Jeannette Potts
Senior Vice President
Patrick Kelly
Senior Vice President
Brian Lesser
Independent Director
Timothy Clackson
Independent Director
Marsha Fanucci
Independent Director
Wayne Frederick
Independent Director
Peter Kolchinsky
Independent Director
Arturo Molina
Independent Director
Selwyn Vickers
Independent Director
Thomas Wiggans
No Data
No Data
About FMTX
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
Webull offers kinds of Forma Therapeutics Holdings Inc stock information, including NASDAQ:FMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FMTX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading FMTX stock methods without spending real money on the virtual paper trading platform.